Low booster uptake in cancer patients despite health benefits.

Figueiredo, Jane C; Levy, Julia; Choi, So Yung; Xu, Alexander M; Merin, Noah M; Hamid, Omid; Lemos, Tucker; Nguyen, Nathalie; Nadri, Maimoona; Gonzalez, Alma; Mahov, Simeon; Darrah, Justin M; Gong, Jun; Paquette, Ronald L; Mita, Alain C; Vescio, Robert A; Salvy, Sarah J; Mehmi, Inderjit; Hendifar, Andrew E; Natale, Ronald; Tourtellotte, Warren G; Ramanujan, V Krishnan; Huynh, Carissa A; Sobhani, Kimia; Reckamp, Karen L; Merchant, Akil A

Figueiredo, Jane C; Levy, Julia; Choi, So Yung; Xu, Alexander M; Merin, Noah M; Hamid, Omid; Lemos, Tucker; Nguyen, Nathalie; Nadri, Maimoona; Gonzalez, Alma; Mahov, Simeon; Darrah, Justin M; Gong, Jun; Paquette, Ronald L; Mita, Alain C; Vescio, Robert A; Salvy, Sarah J; Mehmi, Inderjit; Hendifar, Andrew E; Natale, Ronald; Tourtellotte, Warren G; Ramanujan, V Krishnan; Huynh, Carissa A; Sobhani, Kimia; Reckamp, Karen L; Merchant, Akil A.

Afiliación

Figueiredo JC; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Levy J; Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Choi SY; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Xu AM; Biostatistics Shared Resource, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Merin NM; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Hamid O; Division of Hematology and Cellular Therapy, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Lemos T; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Nguyen N; The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA 90025, USA.
Nadri M; Division of Hematology and Cellular Therapy, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Gonzalez A; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Mahov S; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Darrah JM; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Gong J; Division of Hematology and Cellular Therapy, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Paquette RL; Division of Hematology and Cellular Therapy, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Mita AC; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Vescio RA; Division of Hematology and Cellular Therapy, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Salvy SJ; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Mehmi I; Division of Hematology and Cellular Therapy, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Hendifar AE; Research Center for Health Equity, Department of Biomedical Sciences, Los Angeles, CA 90048, USA.
Natale R; The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA 90025, USA.
Tourtellotte WG; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Ramanujan VK; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Huynh CA; Department of Neurology, Neurological Surgery and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Sobhani K; Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Reckamp KL; Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Merchant AA; Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

iScience ; 27(9): 110596, 2024 Sep 20.

Article en En | MEDLINE | ID: mdl-39286512

ABSTRACT

ABSTRACT

Patients with cancer are at increased risk of death from COVID-19 and have reduced immune responses to SARS-CoV2 vaccines, necessitating regular boosters. We performed comprehensive chart reviews, surveys of patients attitudes, serology for SARS-CoV-2 antibodies and T cell receptor (TCR) ß sequencing for cellular responses on a cohort of 982 cancer patients receiving active cancer therapy accrued between November-3-2020 and Mar-31-2023. We found that 92 · 3% of patients received the primer vaccine, 70 · 8% received one monovalent booster, but only 30 · 1% received a bivalent booster. Booster uptake was lower under age 50, and among African American or Hispanic patients. Nearly all patients seroconverted after 2+ booster vaccinations (>99%) and improved cellular responses, demonstrating that repeated boosters could overcome poor response to vaccination. Receipt of booster vaccinations was associated with a lower risk of all-cause mortality (HR = 0 · 61, p = 0 · 024). Booster uptake in high-risk cancer patients remains low and strategies to encourage booster uptake are needed.

Palabras clave

Cancer; Disease; Immunity; Patient social context

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google